{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-077357","form_type":"8-K","ticker":"SXTP","cik":"0001946563","company_name":"60 DEGREES PHARMACEUTICALS, INC.","filed_at":"2023-09-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.108860+00:00","generated_at":"2026-06-10T15:27:09.284902+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"60 Degrees Pharma withdraws COVID Phase IIB IND after FDA comments; will resubmit pending feasibility","bullets":["Withdrew IND for ACLR8-LR Phase IIB study of tafenoquine for COVID-19 due to FDA comments on study design.","Plans to submit revised IND in Q4 2023 pending assessment of feasibility to meet FDA expectations.","Paused start-up activities for the trial, decreasing short-term burn rate and improving cash position.","Will continue commercialization of ARAKODA (tafenoquine) for malaria and prepare IND for babesiosis.","Q2 2023 ARAKODA sales increased 150% YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-077357","json":"https://secwatch.observer/filing/0001213900-23-077357.json","markdown":"https://secwatch.observer/filing/0001213900-23-077357.md","text":"https://secwatch.observer/filing/0001213900-23-077357.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1946563/000121390023077357/0001213900-23-077357-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1946563/000121390023077357/ea185353-8k_60degrees.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T15:27:09.284902+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}